Compare · CNC vs SERA
CNC vs SERA
Side-by-side comparison of Centene Corporation (CNC) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.81B, about 408.7x SERA ($80.3M).
- SERA has been more active in the news (13 items in the past 4 weeks vs 12 for CNC).
- CNC has more recent analyst coverage (25 ratings vs 8 for SERA).
- Company
- Centene Corporation
- Sera Prognostics Inc.
- Price
- -
- -
- Market cap
- $32.81B
- $80.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 13
- Recent ratings
- 25
- 8
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest CNC
- CENTENE CORPORATION TO HOST 2026 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL
- CENTENE SUBSIDIARY MERIDIAN HEALTH PLAN OF ILLINOIS AWARDED ILLINOIS MEDICAID CONTRACT
- Director Tyler Lauren M was granted 61 shares (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 465 shares, increasing direct ownership by 2% to 25,213 units (SEC Form 4)
- Director Tanji Kenneth was granted 581 shares, increasing direct ownership by 5% to 12,490 units (SEC Form 4)
- Director Eppinger Frederick H was granted 833 shares, increasing direct ownership by 0.23% to 369,538 units (SEC Form 4)
- Director Coughlin Christopher J was granted 562 shares, increasing direct ownership by 3% to 18,711 units (SEC Form 4)
- Health Net Providing Special Assistance to Members and Providers Affected by Palos Warehouse Fire in Los Angeles
- RBC Capital Mkts initiated coverage on Centene with a new price target
- CENTENE APPOINTS LAUREN M. TYLER TO BOARD OF DIRECTORS
Latest SERA
- Director Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)
- Director Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)
- Director Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)
- Director Kamdar Kim P. was granted 25,847 shares, increasing direct ownership by 79% to 58,420 units (SEC Form 4)
- Director Critchfield Gregory C was granted 24,020 shares, increasing direct ownership by 3% to 846,886 units (SEC Form 4)
- Director Capone Mark Christopher was granted 44,379 shares (SEC Form 4)
- Director Barlow Jane F was granted 24,375 shares, increasing direct ownership by 107% to 47,088 units (SEC Form 4)
- PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
- SEC Form 3 filed by new insider Capone Mark Christopher
- Sera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits